About anebulo pharmaceuticals inc - ANEB
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. Its product candidate, Selonabant, is a small molecule antagonist of cannabinoid binding receptor type-1. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.
ANEB At a Glance
Anebulo Pharmaceuticals, Inc.
1017 Ranch Road 620 South
Lakeway, Texas 78734
| Phone | 1-512-598-0931 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -8,484,763.00 | |
| Sector | Health Technology | Employees | 3 | |
| Fiscal Year-end | 06 / 2026 | |||
| View SEC Filings |
ANEB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.075 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.019 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
ANEB Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,828,254.333 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ANEB Liquidity
| Current Ratio | 24.529 |
| Quick Ratio | 24.529 |
| Cash Ratio | 23.843 |
ANEB Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -104.629 |
| Return on Equity | -109.69 |
| Return on Total Capital | -72.781 |
| Return on Invested Capital | -109.69 |
ANEB Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |